ENDRA Life Sciences Inc.
ENDRA Life Sciences Inc. is listed today as Endra Life Sciences Inc.: market value, financials and filings are on its company page.
Funding rounds
0 counted as startup funding, 4 other private sales on record. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Oct 2025 | $14 M | Private placement after listing | $10 to $50 million | equity | SEC | |
| Dec 2019 | $9 M | Private placement after listing | $2 to $10 million | equity, debt | SEC | |
| Jul 2019 | $3 M | Private placement after listing | $2 to $10 million | debt, options | SEC | |
| Jun 2018 | $1 M | Private placement after listing | Under $2 million | equity, debt | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
ENDRA Life Sciences Inc. had no revenue when it filed its newest notice of a funding round (Oct 2025).
SEC Form D (revenue range) · Oct 2025
Revenue range over time, as stated in its notices: revenue of up to $1 million in 2018; revenue of up to $1 million in 2019; no revenue in 2025.
SEC Form D (revenue range) · Oct 2025
The industry group it chose in its notices: Biotechnology.
SEC Form D · Oct 2025
Products and services#
No products or services of ENDRA Life Sciences Inc. are on record.
Investors#
No investor of ENDRA Life Sciences Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete.
Largest shareholders today
Institutions holding Endra Life Sciences Inc. shares, as of Sep 30, 2026.
- Altium Capital Management LLC$0 M3.64%
- Citizens Financial Group Inc/ri$0 M1.89%
- Citadel Advisors LLC$0 M1.38%
- Renaissance Technologies LLC$0 M1.25%
- Geode Capital Management, LLC$0 M0.99%
- Vanguard Fiduciary Trust Co$0 M0.67%
- Vanguard Capital Management LLC$0 M0.49%
- UBS Group AG$0 M0.40%
- Morgan Stanley$0 M0.24%
- Citigroup Inc$0 M0.07%
- Tower Research Capital LLC (TRC)$0 M0.06%
- Northwestern Mutual Wealth Management Co$0 M0.00%
Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Alexander Tokman | Executive officer | Oct 2025 |
| Michael Thornton | Executive officer | Oct 2025 |
| Richard Jacroux | Executive officer | Oct 2025 |
| David R. Wells | Executive officer | Dec 2019 |
| Francois R. Michelon | Executive officer | Dec 2019 |
| Michael R. Thornton | Executive officer | Dec 2019 |
| Alexander Tokman | Director | Oct 2025 |
| Anthony J. DiGiandomenico | Director | Oct 2025 |
| Louis J. Basenese | Director | Oct 2025 |
| Michael J. Harsh | Director | Oct 2025 |
| Alexander S. Tokman | Director | Dec 2019 |
| Anthony R. DiGiandomenico | Director | Dec 2019 |
| Francois R. Michelon | Director | Dec 2019 |
| Michael S. Harsh | Director | Dec 2019 |
| Sanjiv S. Gambhir | Director | Dec 2019 |
| Alexander Y. Tokman | Director | Jul 2019 |
Went public since 2017. Its SEC number is that of a company listed on a stock exchange.